Heart & blood pressure · Huntsville, AL
Heart and blood pressure studies in Huntsville, AL
15 recruiting studies have a site in Huntsville.
15 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- Recruiting
Prevail Global Study
Medtronic Vascular
- Location
- Huntsville, AL + 53 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
AstraZeneca
- Location
- Huntsville, AL + 151 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Alnylam Pharmaceuticals
- Location
- Huntsville, AL + 213 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
AstraZeneca
- Location
- Huntsville, AL + 93 other US sites
- Eligibility basics
- Ages 18–130
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Huntsville, AL + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Eli Lilly and Company
- Location
- Huntsville, AL + 28 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
Boston Scientific Corporation
- Location
- Huntsville, AL + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
CSL Behring
- Location
- Huntsville, AL + 147 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Huntsville, AL + 117 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
- Location
- Huntsville, AL + 193 other US sites
- Eligibility basics
- Ages 50–105
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
- Location
- Huntsville, AL + 47 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2/Phase 3
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Kardigan, Inc.
- Location
- Huntsville, AL + 46 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Novartis Pharmaceuticals
- Location
- Huntsville, AL + 29 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
DalCor Pharmaceuticals
- Location
- Huntsville, AL + 112 other US sites
- Eligibility basics
- Ages 45+
- Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
Edwards Lifesciences
- Location
- Huntsville, AL + 49 other US sites
- Eligibility basics
- Ages 65+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.